Publication:
Plasma amino acid profile in autism spectrum disorder (ASD)

dc.contributor.coauthorBala, K. A.
dc.contributor.coauthorDogan, M.
dc.contributor.coauthorKaba, S.
dc.contributor.coauthorAslan, O.
dc.contributor.coauthorBalahoroglu, R.
dc.contributor.coauthorCokluk, E.
dc.contributor.coauthorUstyol, L.
dc.contributor.coauthorKocaman, S.
dc.contributor.departmentSchool of Medicine
dc.contributor.facultymemberYes
dc.contributor.kuauthorMutluer, Tuba
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T22:50:33Z
dc.date.issued2016
dc.description.abstractOBJECTIVE: In our study, we aimed to reveal pathophysiologic mechanisms in ASD by comparing plasma amino acid levels between patients and healthy controls while considering vitamin B12 and D levels. PATIENTS and METHODS: The study included 21 patients aged 2-18 years-old who were followed with a diagnosis autism spectrum disorder (ASD) and 21 age and sex-matched healthy children from our outpatient clinic as control group. RESULTS: The study included 42 children and adolescents aged 2-18 years-old (19 girls and 23 boys). There were no significant differences in terms of body weight and height between the groups. We found significant differences in levels of ammonium, phosphoethanolamine, histidine, homocysteine, carnosine, methionine, cystathionine, cyste0ine, threonine, 3-methyl histidine and phenylalanine/tyrosine ratio between patient and control groups. Both vitamin B12 and D were significantly lower in the ASD group compared to controls. In the variance analysis with vitamin B12 and D as covariates, significant differences persisted for only phosphoethanolamine (p=0.04), cystathionine (p<0.001), cystine (p=0.006) and threonine (p=0.02). CONCLUSIONS: Further studies are needed on the amino acids that show variations in children with ASD in order to reveal their role in the etiology and therapeutic use in ASD.
dc.description.fulltextNo
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.peerreviewstatusN/A
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionN/A
dc.identifier.embargoN/A
dc.identifier.issn1128-3602
dc.identifier.quartileQ3
dc.identifier.scopus2-s2.0-85016943527
dc.identifier.urihttps://hdl.handle.net/20.500.14288/6672
dc.identifier.wos373350100025
dc.keywordsPlasma amino acids
dc.keywordsAutism spectrum disorder
dc.keywordsChildren
dc.keywordsAdolescent
dc.keywordsPsychotic disorder
dc.keywordsRisk-factors
dc.keywordsChildren
dc.keywordsPhosphoethanolamine
dc.language.isoeng
dc.publisherVerduci Editore
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofEuropean Review for Medical and Pharmacological Sciences
dc.relation.openaccessN/A
dc.rightsN/A
dc.subjectPharmacology
dc.subjectPharmacy
dc.titlePlasma amino acid profile in autism spectrum disorder (ASD)
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorMutluer, Tuba
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files